NOX1 and chronic obstructive pulmonary disease: These data demonstrate novel therapeutic potential of targeting NOX1 and NOX4 for the attenuation of oxidative and inflammatory responses during the early stage of COPD development, whereas for the treatment of end-stage COPD, inhibition of NOX isoforms 1, 2, 4, and 5 is necessary.